Cadherin

Cadherin 17: A Target Opportunity To Develop Effector-Enhanced Drug Modalities - ResearchAndMarkets.com

Retrieved on: 
Friday, August 5, 2022

The "Cadherin 17: A Target Opportunity To Develop Effector-Enhanced Drug Modalities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cadherin 17: A Target Opportunity To Develop Effector-Enhanced Drug Modalities" report has been added to ResearchAndMarkets.com's offering.
  • There are more than 100 types of cadherins in humans, and many of them are not only responsible for cell adhesion but also involved in tumorigenesis.
  • CDH17 provides a great opportunity for drug discovery and development as the competitive landscape still is very favorable for new entrants, but the first molecules have entered clinical development.
  • The scientific rationale for CDH17-targeted therapies based on target characteristics and its differential expression profile;
    Preclinical proof-of-concept of CDH17-targeted different drug modalities;
    Clinical indications suitable for development of CDH17-targeted therapies and their patient populations;
    The competitive landscape of CDH17-targeted drug modalities in development;
    Specific profiles of CDH17-targeted drug modalities; and
    Profiles of companies active in the development of anti-CDH17 therapy candidates.

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies Bundle Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 4, 2022

The "Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis" report has been added to ResearchAndMarkets.com's offering.
  • This report bundle includes four reports about novel cancer targets which have in common a compelling target expression profile with a low risk of on-target/off-tumor toxicity.
  • The tetraspan membrane protein is a member of the claudin family of tight junction proteins.
  • The transmembrane protein CLDN6 is virtually absent from any normal tissue, whereas it is aberrantly and frequently expressed in various cancers of high medical need.